Loyal Valley Capital
Deal focus: Pop Mart dominates China’s dolls
Best known in China for the Molly series of fashion dolls, Pop Mart emerged as a leader before many others recognized the market potential. The Loyal Valley Capital-backed company is now preparing for an IPO
Chinese toy figurine retailer Pop Mart raises $100m
Chinese black-box doll retailer Pop Mart has raised more than $100 million in funding from China Renaissance and Loyal Valley Capital in what is expected to be its last round before an IPO.
Akeso Biopharma trades up after $333m Hong Kong IPO
Akeso Biopharma, a private equity-backed Chinese drug developer specializing in treatments that use the immune system to fight cancer, saw its stock jump 50% in early trading on the Hong Kong Stock Exchange following a HK$2.58 billion ($333 million) IPO.
Temasek leads $70m Series C for China's Abbisko Therapeutics
Temasek Holdings has led a $70 million Series C round for Chinese drug developer Abbisko Therapeutics.
China's Loyal Valley recruits ex-Blackstone executive
Brian Chi, who previously spent more than a decade making China investments for The Blackstone Group and Morgan Stanley Private Equity Asia (MSPEA), has joined Loyal Valley Capital as a partner.
PE-backed InnoCare raises $288m in Hong Kong IPO
InnoCare Pharma, a private equity-backed Chinese drug developer focused on treatments for cancer and autoimmune diseases, has raised HK$2.24 billion ($288 million) through a Hong Kong IPO.
Chinese drug developer RemeGen raises $100m
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
Trustbridge backs Chinese storytelling start-up
Chinese children’s storytelling start-up Kaishu Story, also known as Kaishu Jianggushi, has raised $66 million in an extended tranche of Series C round led by Trustbridge Partners.
PE-backed Akeso Biopharma targets Hong Kong IPO
Chinese biotech player Akeso Biopharma has made a second attempt at filing for a Hong Kong IPO after its previous application was rejected last month for failing to meet regulatory requirements.
China’s Loyal Valley closes second US dollar fund at $465m
China’s Loyal Valley Capital has closed its second US dollar-denominated fund at $465 million. The target was $400 million with a hard cap of $440 million.
Chinese antibody drug developer raises $150m
Akeso Biopharma, a Chinese biotech company specializing in antibody drugs, has raised a $150 million Series D round led by Loyal Valley Capital and Sino Biopharm.
China secondaries: Curious conversions
An exit lag and difficulties raising money for renminbi funds in China has created a novel opening for secondaries investors comfortable moving assets from one currency to another
China’s Allist Pharmaceuticals raises $171m Series A
Shanghai-based drug developer Allist Pharmaceuticals has raised RMB1.2 billion ($171 million) in a Series A round of funding led by Shiyu Capital. Other participants include Loyal Valley Capital and Suzhou Industrial Park Bioventure Investment.
China online education: Passing the test?
Capital has poured into China’s online education sector in recent years, but with losses mounting and valuations called into question, investors are finding that not all business models are created equal
Deal focus: Gaosi Education stresses its B2B credentials
As China's mainstream online tuition players battle for the hearts, minds and wallets of end users, Gaosi Education found a niche targeting the B2B market. It recently raised $140 million to accelerate expansion
Warburg Pincus leads Series D for China's Gaosi Education
Gaosi Education, which provides tutoring services to schools and other educational institutions in China, has raised $140 million in Series D funding led by Warburg Pincus.
Qiming leads $42m Series B for China cancer drug developer
Qiming Venture Partners has led a $42 million Series B round for Chinese cancer drug developer Abbisko.
FOMO is the biggest risk for China investors - AVCJ Forum
The best way for private equity and venture capital investors to manage their China risk is to not deploy capital if they are only motivated by a fear of missing out (FOMO), GPs told the AVCJ China Forum.
Asia GP-led secondaries hit record high in 2018
An increase in GP-led transactions propelled Asia secondary market volume to $7.8 billion last year, and more of the same is expected in 2019 – once managers have adjusted their mark-to-market valuations following fourth-quarter volatility in the public...
China biotech player Innocare raises $160m
China’s Loyal Valley Capital has led a $160 million funding round for Beijing Innocare, a biotechnology developer focused on immuno-oncology and autoimmune diseases.
Fosun-owned Henlius Biotech files for Hong Kong IPO
Shanghai Henlius Biotech, a Chinese drug developer controlled by Fosun Group, has filed for a Hong Kong IPO. Third-party investors include Loyal Valley Capital and China International Capital Corporation (CICC).
Junshi Biosciences seeks up to $414m in HK offering
Shanghai Junshi Biosciences, a Chinese drug developer backed by Hillhouse Capital, is seeking to raise up to HK$3.2 billion ($414 million) through a Hong Kong IPO.